Korsana Biosciences, Inc.

Provide interim proof-of-concept data for KRSA-028 in Alzheimer's patients

Deadline not yet reached (521 days left)

Announced: 11 Sep 2026
Due: 31 Mar 2028

Deadline
Met
Late
Not met
Today

What the company said

“interim proof-of-concept data evaluating amyloid plaque clearance in Alzheimer's disease patients anticipated by the end of 2027 or the first quarter of 2028”

SourceKorsana Biosciences, Inc. Form 8-K press release, 2026-09-11
FilingSEC filing index
Deadline as statedby the end of 2027 or the first quarter of 2028
Deadline used31 Mar 2028, the last day of the stated period
TypeProduct
Permanent referenceKI-C-2026-KRSA-000653
Cite as https://keptindex.org/c/KI-C-2026-KRSA-000653/ — this address never changes.

What we found

The deadline has not passed yet, so there is nothing to check. We look for evidence starting 30 days after 31 Mar 2028.

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Clinical readout
Indicative materiality: Medium rules
Action: Provide
Language: Expected (“expects”, “plans”)

Tell me what happens

This deadline has not been settled yet. We check 30 days after it passes. Get an email when we record the outcome.

Alert me when this resolves

How this entry was checked

Commitment recordedRecorded from the company's filing.
OutcomeNot yet assessed. Nothing is judged before the deadline.

Are you Korsana Biosciences, Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2026-KRSA-000653 · Corrections policy